Nausea medicines are pharmaceutical products used for the treatment of nausea and vomiting. These medicines works by blocking the effects of histamine and serotonin in the brain and gastrointestinal tract. Nausea and vomiting are commonly experienced during chemotherapy treatment for cancer, as well as during pregnancy. Nausea medicines helps reduce nausea and allows patients to continue with their regimen. Some of the commonly used nausea medicines includes ondansetron, dolasetron, granisetron, and tropisetron.
The global nausea medicine market is estimated to be valued at US$ 2.8 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global nausea medicine market is witnessing high growth owing to increasing prevalence of diseases causing nausea like cancer, gastrointestinal infections, liver diseases, and morning sickness during early pregnancy stages. Growing number of cancer cases undergoing chemotherapy has significantly contributed to the market growth. According to World Health Organization, cancer burden is estimated to grow to 27 million new cancer cases and 16.3 million cancer deaths by 2040. Increasing R&D investments by key players for development of advanced therapeutics to treat nausea is further propelling the market growth.
Market Dynamics:
The nausea medicine market is driven by high prevalence of diseases causing nausea. As per WHO, cancer burden is growing significantly and is estimated to increase by over 70% in next two decades. During chemotherapy for cancer treatment, around 70-80% patients suffer from chemotherapy induced nausea and vomiting (CINV). Growing cancer cases undergoing chemotherapy is a major driver for nausea medicine market.
Another driver for this market is increasing prevalence of gastrointestinal infections and liver diseases globally. Gastrointestinal infections and liver diseases are among leading causes of nausea worldwide. Diseases like hepatitis, cirrhosis, typhoid and food poisoning commonly causes nausea. According to WHO reports, prevalence of viral hepatitis and other liver diseases is growing rapidly. Increasing burden of gastrointestinal and liver diseases is expected to propel demand for antiemetics over the forecast period.
SWOT Analysis
Strength: The nausea medicine market has several established branded drugs with strong brand recognition and loyalty. These drugs have proven efficacy and safety profiles established over decades of use. Short-acting antiemetic drugs provide rapid relief from nausea and allow patients to resume normal activities quickly.
Weakness: Patents for many blockbuster nausea drugs will expire in the coming years, allowing generic competition to erode sales and margins. Side effects of certain antiemetics like drowsiness and constipation can reduce patient compliance. Developing new innovative drugs requires huge investments with uncertain returns.
Opportunity: Rising incidence of cancer, chemotherapy-induced nausea and post-surgical nausea point to increased demand. Opportunities exist in developing countries with growing healthcare spending. Novel drug delivery mechanisms could improve patient adherence to antiemetic regimens.
Threats: Price controls and drug price negotiation policies pose pricing challenges in select markets. Safety issues with select drugs may impact brand images and sales. Patented drugs also face competition from cheaper generic substitutes after patent expiry. Emergence of alternative therapies may reduce dependence on pharmaceutical interventions.
Key Takeaways
The global nausea medicine market is expected to witness high growth over the forecast period driven by rising cancer incidence worldwide requiring chemotherapy treatments. The market size is projected to reach USD 2.8 billion by 2024, growing at a CAGR of 6.3% between 2023-2030.
Regional analysis: North America dominates currently due to high healthcare spending and rapid adoption of new drugs. However, Asia Pacific region is expected to witness highest growth led by China and India with growing patient populations and healthcare infrastructure Development.
Key players: Key players operating in the nausea medicine market include GlaxoSmithKline plc, Pfizer Inc. Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company. These market leaders are focusing on developing patented improved formulations and exploring emerging markets for future growth.
